ClinicalTrials.gg
Not yet recruitingNCT07942857Updated Nov 17, 2026

Advanced Reticulocyte Parameters in Hemolytic Anemias

An observational study in Thalassemia, Sickle Cell Disease and Hemolytic Anemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Assiut University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
90
Ages
18 Years and older
Sex
All
01

Study summary

This cross-sectional study aims to evaluate advanced reticulocyte parameters in patients with thalassemia and sickle cell disease compared with healthy controls.

Read the detailed description

Hemolytic anemia is characterized by premature destruction of red blood cells. Reticulocytes are immature red blood cells released from the bone marrow, and their assessment reflects erythropoietic activity.

Modern automated hematology analyzers provide advanced reticulocyte parameters including reticulocyte percentage, absolute reticulocyte count, reticulocytes with low, medium and high ribonucleic acid (RNA) content, immature reticulocyte fraction, mean reticulocyte volume, and reticulocyte hemoglobin content.

This observational study will measure these advanced reticulocyte parameters in adult patients with beta-thalassemia, patients with sickle cell disease, and healthy controls.

02

Conditions studied

  • Thalassemia
  • Sickle Cell Disease
  • Hemolytic Anemia

Keywords

  • Reticulocyte parameters
  • Immature reticulocyte fraction
  • Thalassemia
  • Sickle cell disease
  • Assiut
03

In context

Thalassemia

250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.

This study's planned enrollment of 90 is below the median of 106 across 70 observational studies indexed under Thalassemia.

Browse Thalassemia studies →

Lead sponsor

Assiut University is the lead sponsor of 5,088 studies on the registry; 2,185 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with beta-thalassemia, patients with sickle cell disease, and healthy controls attending Assiut University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Patients with beta-thalassemia
  • Patients with sickle cell disease
  • Healthy controls
  • Written

Exclusion criteria

Exclusion Criteria:

  • - Other types of anemia
  • Recent blood transfusion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Thalassemia Patients

    Patients diagnosed with beta-thalassemia.

  • Sickle Cell Disease Patients

    Patients diagnosed with sickle cell disease.

  • Healthy Controls

    Apparently healthy individuals without anemia or hemoglobinopathy.

06

What researchers measure

Primary outcomes

  1. Immature reticulocyte fraction

    Mean immature reticulocyte fraction measured by automated hematology analyzer (percentage).

    Time frame: Baseline

Secondary outcomes

  1. Absolute reticulocyte count

    Mean absolute reticulocyte count measured by automated hematology analyzer (cells per microliter).

    Time frame: Baseline

  2. Reticulocyte percentage

    Mean reticulocyte percentage measured by automated hematology analyzer.

    Time frame: Baseline

  3. Reticulocyte hemoglobin content

    Mean reticulocyte hemoglobin content measured by automated hematology analyzer (picograms).

    Time frame: Baseline

  4. Mean reticulocyte volume

    Mean reticulocyte volume measured by automated hematology analyzer (femtoliters).

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 26, 2026
Primary completionEst.
Nov 25, 2027
CompletionEst.
Mar 20, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942857
Lead sponsor
Assiut University
Responsible party
Kholoud Abdelsattar Ahmed Abdelhaleim (Resident Physician, Department of Clinical Pathology, Assiut University) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 26, 2026 (estimated)
Primary completion
Nov 25, 2027 (estimated)
Completion
Mar 20, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Kholoud A Ahmed, Resident
Contact
khloud.18313224@med.aun.edu.eg
01553673654
Hisham A Abdel-Baset, prof
study chair · Clinical pathology Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion